Safety was also evaluated in 173 adult patients with relapsed or refractory lymphoma who received POLIVY, bendamustine, and either a rituximab product or obinutuzumab in Study GO29365, including the 45 patients with DLBCL described above. In the expanded safety population, the median age was 66 years (range 27 – 86), 57% were male, 91% had an ECOG performance status of 0-1, and 32% had a history of peripheral neuropathy at baseline.
Fatal adverse reactions occurred in 4.6% of recipients of POLIVY within 90 days of last treatment, with infection as a leading cause. Serious adverse reactions occurred in 60%, most often from infection.
- General disorders: infusion-related reaction (7%)
- Infection: upper respiratory tract infection (16%), lower respiratory tract infection (10%), herpesvirus infection (12%), cytomegalovirus infection (1.2%)
- Respiratory: dyspnea (19%), pneumonitis (1.7%)
- Nervous system disorders: dizziness (10%)
- Investigations: weight decrease (10%), transaminase elevation (8%), lipase increase (3.5%)
- Musculoskeletal disorders: arthralgia (7%)
- Eye disorders: blurred vision (1.2%)
Strong CYP3A Inhibitors
Concomitant use with a strong CYP3A4 inhibitor may increase unconjugated MMAE AUC [see Clinical Pharmacology (12.3)], which may increase POLIVY toxicities. Monitor patients for signs of toxicity.
Strong CYP3A Inducers
Concomitant use with a strong CYP3A4 inducer may decrease unconjugated MMAE AUC [see Clinical Pharmacology (12.3)].
Risk Summary
Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], POLIVY can cause fetal harm. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of the small molecule component of POLIVY, MMAE, to pregnant rats during organogenesis at exposures below the clinical exposure at the recommended dose of 1.8 mg/kg POLIVY every 21 days resulted in embryo-fetal mortality and structural abnormalities (see Data). Advise a pregnant woman of the potential risks to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Data
Animal Data
No embryo-fetal development studies in animals have been performed with polatuzumab vedotin-piiq. In an embryo-fetal developmental study in pregnant rats, administration of two intravenous doses of MMAE, the small molecule component of POLIVY, on gestational days 6 and 13 caused embryo-fetal mortality and structural abnormalities, including protruding tongue, malrotated limbs, gastroschisis, and agnathia compared to controls at a dose of 0.2 mg/kg (approximately 0.5-fold the human area under the curve [AUC] at the recommended dose).
Risk Summary
There is no information regarding the presence of polatuzumab vedotin-piiq in human milk, the effects on the breastfed child, or milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with POLIVY and for 2 months after the last dose.
Pregnancy Testing
Verify pregnancy status in females of reproductive potential prior to initiating POLIVY [see Use in Specific Populations (8.1)].
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with POLIVY and for 3 months after the last dose [see Nonclinical Toxicology (13.1)].
Males
Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with POLIVY and for 5 months after the final dose [see Nonclinical Toxicity (13.1)].
Infertility
Females
Based on findings in animal studies with MMAE-containing antibody-drug conjugates (ADCs), POLIVY may impair female fertility. The effect on fertility is reversible [see Nonclinical Toxicology (13.1)].
Males
Based on findings from animal studies, POLIVY may impair male fertility. The reversibility of this effect is unknown [see Nonclinical Toxicology (13.1)].
Cardiac Electrophysiology
Polatuzumab vedotin-piiq did not prolong the mean QTc interval to any clinically relevant extent based on ECG data from two open-label studies in patients with previously treated B-cell malignancies at the recommended dosage.
Distribution
The acMMAE central volume of distribution is 3.15 L. For humans, MMAE plasma protein binding is 71% to 77% and the blood-to-plasma ratio is 0.79 to 0.98, in vitro.
Elimination
At the end of Cycle 6, the median (min, max) acMMAE terminal half-life was 12.2 days (4.5 to 36.7 days) and the clearance was 0.9 L/day in patients with B-cell malignancies. The median (min, max) unconjugated MMAE terminal half-life was 3.74 days (1.58 to 10.1 days) days after the first polatuzumab vedotin-piiq dose.
Metabolism
Polatuzumab vedotin-piiq catabolism has not been studied in humans; however, it is expected to undergo catabolism to small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites. MMAE is a substrate for CYP3A4.
Specific Populations
No clinically significant differences in the pharmacokinetics of acMMAE or unconjugated MMAE were observed based on age (19 to 89 years), sex (males versus females), race (White 69%, Asian 11%), or mild to moderate renal impairment (CLcr 30 to 89 mL/min).
The effect of severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease with or without dialysis on the pharmacokinetics of acMMAE or unconjugated MMAE is unknown.
Patients with Hepatic Impairment
Compared to patients with normal hepatic function, geometric mean MMAE exposure was 11% higher in patients with previously untreated DLBCL and mild hepatic impairment (total bilirubin 1 to 1.5 × ULN or any AST greater than ULN) and 40% higher in patients with relapsed or refractory DLBCL and mild hepatic impairment. The effect of mild hepatic impairment on MMAE exposure is not expected to have a clinically significant impact.
Mild hepatic impairment was not associated with a significant difference in acMMAE exposure. The effect of moderate to severe hepatic impairment (total bilirubin greater than 1.5 × ULN and any AST) or liver transplantation on the pharmacokinetics of acMMAE or unconjugated MMAE is unknown.
Drug Interaction Studies
No dedicated clinical drug-drug interaction studies with POLIVY in humans have been conducted.
Physiologically-Based Pharmacokinetic (PBPK) Modeling Predictions:
Strong CYP3A Inhibitor: Concomitant use of polatuzumab vedotin-piiq with ketoconazole (strong CYP3A inhibitor) is predicted to increase unconjugated MMAE AUC by 45%.
Strong CYP3A Inducer: Concomitant use of polatuzumab vedotin-piiq with rifampin (strong CYP3A inducer) is predicted to decrease unconjugated MMAE AUC by 63%.
Sensitive CYP3A Substrate: Concomitant use of polatuzumab vedotin-piiq is predicted not to affect exposure to midazolam (sensitive CYP3A substrate).
Population Pharmacokinetic (popPK) Modeling Predictions:
Bendamustine or Rituximab: No clinically significant differences in the pharmacokinetics of acMMAE or unconjugated MMAE are predicted when polatuzumab vedotin-piiq is used concomitantly with bendamustine or rituximab.
Rituximab, Cyclophosphamide, Doxorubicin, or Prednisone (R-CHP): No clinically significant differences in the pharmacokinetics of acMMAE or unconjugated MMAE are predicted when polatuzumab vedotin-piiq is used concomitantly with R-CHP.
In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically:
Cytochrome P450 (CYP) Enzymes: MMAE does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. MMAE does not induce major CYP enzymes.
Transporter Systems: MMAE does not inhibit P-gp. MMAE is a P-gp substrate.
GO39942 (POLARIX)
The efficacy of POLIVY was evaluated in POLARIX (NCT03274492), a randomized double-blind, placebo-controlled, multicenter trial in patients with previously untreated large B-cell lymphoma. Eligible patients were aged 18–80 and had an International Prognostic Index (IPI) score of 2–5 and ECOG performance status of 0–2. The study excluded patients with transformed lymphoma, primary mediastinal large B-cell lymphoma, known CNS lymphoma, or Grade 2 or higher peripheral neuropathy.
Patients were randomized in a 1:1 ratio to receive POLIVY plus R-CHP or to receive R-CHOP for six 21-day cycles followed by two additional cycles of rituximab alone in both arms. Randomization was stratified by IPI score (2 vs 3–5), presence or absence of bulky disease (lesion ≥7.5 cm), and geographical region. Dosing in each treatment arm was as follows:
- POLIVY + R-CHP arm: POLIVY 1.8 mg/kg intravenously, rituximab 375 mg/m2 intravenously, cyclophosphamide 750 mg/m2 intravenously, and doxorubicin 50 mg/m2 intravenously on Day 1 and prednisone 100 mg orally once daily on Days 1–5 for 6 cycles. Rituximab 375 mg/m2 was administered intravenously on Day 1 of cycles 7 and 8.
- R-CHOP arm: rituximab 375 mg/m2 intravenously, cyclophosphamide 750 mg/m2 intravenously, doxorubicin 50 mg/m2 intravenously, and vincristine 1.4 mg/m2 intravenously on Day 1 and prednisone 100 mg orally once daily on Days 1–5 for 6 cycles. Rituximab 375 mg/m2 was administered intravenously on Day 1 of cycles 7 and 8.
Prophylaxis with granulocyte-colony stimulating factor (G-CSF) was mandated for both arms. Dosing in both treatment arms was preceded by premedication.
Of the 879 patients randomized (440 to POLIVY plus R-CHP, 439 to R-CHOP), the median age was 65 years (range 19 to 80 years), 54% were male, 54% were White, 19% were Asian, 1.8% were Black or African American, and 6% were Hispanic or Latino. In total, 38% had an IPI score of 2, 62% had an IPI score of 3–5, 89% had Stage 3 or 4 disease, and 44% had bulky disease. The majority of patients had DLBCL, NOS (84%; n = 740), 11% (n = 93) had HGBL with MYC and BCL2 and/or BCL6 rearrangements or HGBL, NOS, and 5% had other large B-cell lymphomas.
Efficacy was based on investigator-assessed progression-free survival (PFS). Other efficacy measures included modified event-free survival. Efficacy results are summarized in Table 12 and in Figure 1.
Table 12 Summary of Efficacy in POLARIX by Intention-to-Treat Analysis| Outcomes | POLIVY + R-CHP n = 440 | R-CHOP n = 439 |
|---|
| CI=confidence interval; CR=complete response; EFS=event-free survival; HR=hazard ratio; PFS=progression-free survival. |
| Progression-Free Survival per Investigator Estimated median follow-up for PFS was 24.7 months in both arms combined. | | |
| Number (%) of patients with event | 107 (24) | 134 (31) |
| Progression | 88 | 114 |
| Death | 19 | 20 |
| HR (95% CI) | 0.73 (0.57, 0.95) |
| p-value Stratified log-rank test, with a two-sided significance boundary of 0.05. The hierarchical testing order was PFS, modified EFS, then CR rate and overall survival. | 0.0177 |
| Modified Event-Free Survival per Investigator Modified EFS was defined as time from randomization to the earliest occurrence of disease progression or relapse, death, an efficacy finding that led to non-protocol specified lymphoma treatment, or biopsy positive for residual disease. | | |
| Number (%) of patients with event | 112 (26) | 138 (31) |
| HR (95% CI) | 0.75 (0.58, 0.96) |
| p-value | 0.0244 |
| Objective Response at End of Treatment By blinded independent central review, per 2014 Lugano response criteria. | | |
| Objective response rate, % (95% CI) | 86 (82, 89) | 84 (80, 87) |
| CR rate, % | 78 (74, 82) | 74 (70, 78) |
| Difference in CR rate, % (95% CI) | 3.9 (–1.9, 9.7) |
| p-value Cochran-Mantel-Haenszel chi-squared test, with a two-sided significance boundary of 0.01. | 0.1557 |
Figure 1 Kaplan-Meier Curve of Investigator-Assessed Progression-Free Survival in POLARIX by Intention-to-Treat Analysis
In a prespecified descriptive analysis of the largest lymphoma subgroup, DLBCL, NOS, the PFS HR was 0.75 (95% CI: 0.57, 0.99). In patients with HGBL, the PFS HR was 0.48 (95% CI: 0.21, 1.08). There were insufficient data to evaluate efficacy in other large B-cell lymphomas.
With an estimated median follow-up of 3.3 years, the prespecified final analysis of overall survival (OS) showed no statistically significant difference, with a HR of 0.94 (95% CI: 0.67, 1.33). In a descriptive analysis, the OS HR in patients with DLBCL, NOS was 1.02 (95% CI: 0.70, 1.49). The OS HR in patients with HGBL was 0.42 (95% CI: 0.15, 1.19).
GO29365
The efficacy of POLIVY was evaluated in Study GO29365 (NCT02257567), an open-label, multicenter clinical trial that included a cohort of 80 patients with relapsed or refractory DLBCL after at least one prior regimen. Patients were randomized 1:1 to receive either POLIVY in combination with bendamustine and a rituximab product (BR) or BR alone for six 21-day cycles. Randomization was stratified by duration of response (DOR) to last therapy. Eligible patients were not candidates for autologous HSCT at study entry. The study excluded patients with Grade 2 or higher peripheral neuropathy, prior allogeneic HSCT, active central nervous system lymphoma, or transformed lymphoma.
Following premedication with an antihistamine and antipyretic, POLIVY was given by intravenous infusion at 1.8 mg/kg on Day 2 of Cycle 1 and on Day 1 of Cycles 2–6. Bendamustine was administered at 90 mg/m2 intravenously daily on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2–6. A rituximab product was administered at a dose of 375 mg/m2 intravenously on Day 1 of Cycles 1–6. The cycle length was 21 days.
Of the 80 patients randomized to receive POLIVY plus BR (n = 40) or BR alone (n = 40), the median age was 69 years (range: 30–86 years), 66% were male, and 71% were White. Most patients (98%) had DLBCL not otherwise specified. The primary reasons patients were not candidates for HSCT included age (40%), insufficient response to salvage therapy (26%), and prior transplant failure (20%). The median number of prior therapies was 2 (range: 1–7), with 29% receiving one prior therapy, 25% receiving 2 prior therapies, and 46% receiving 3 or more prior therapies. Eighty percent of patients had refractory disease to last therapy.
In the POLIVY plus BR arm, patients received a median of 5 cycles, with 49% receiving 6 cycles. In the BR arm, patients received a median of 3 cycles, with 23% receiving 6 cycles.
Efficacy was based on complete response (CR) rate at the end of treatment and DOR, as determined by an independent review committee (IRC). Other efficacy measures included IRC-assessed best overall response.
Response rates are summarized in Table 13.
Table 13 Response Rates in Patients with Relapsed or Refractory DLBCL| Response per IRC, n (%) PET-CT based response per modified Lugano 2014 criteria. Bone marrow confirmation of PET-CT CR was required. PET-CT PR required meeting both PET criteria and CT criteria for PR. | POLIVY + BR n = 40 | BR n = 40 |
|---|
| CR=complete response; PR=partial remission. |
| Objective Response at End of Treatment End of treatment was defined as 6–8 weeks after Day 1 of Cycle 6 or last study treatment. (95% CI) | 18 (45) (29, 62) | 7 (18) (7, 33) |
CR (95% CI) | 16 (40) (25, 57) | 7 (18) (7, 33) |
| Difference in CR rates, % (95% CI) Miettinen-Nurminen method. | 22 (3, 41) |
| Best Overall Response of CR or PR PET-CT results were prioritized over CT results. (95% CI) | 25 (63) (46, 77) | 10 (25) (13, 41) |
Best Response of CR (95% CI) | 20 (50) (34, 66) | 9 (23) (11, 38) |
In the POLIVY plus BR arm, of the 25 patients who achieved a partial or complete response, 16 (64%) had a DOR of at least 6 months, and 12 (48%) had a DOR of at least 12 months. In the BR arm, of the 10 patients who achieved a partial or complete response, 3 (30%) had a DOR lasting at least 6 months, and 2 (20%) had a DOR lasting at least 12 months.
How Supplied
POLIVY (polatuzumab vedotin-piiq) for injection is a preservative-free, white to grayish-white lyophilized powder, which has a cake-like appearance. POLIVY is supplied as:
| Carton Contents | NDC |
|---|
| One 30 mg single-dose vial | NDC 50242-103-01 |
| One 140 mg single-dose vial | NDC 50242-105-01 |
Peripheral Neuropathy
Advise patients that POLIVY can cause peripheral neuropathy. Advise patients to report to their healthcare provider any numbness or tingling of the hands or feet or any muscle weakness [see Warnings and Precautions (5.1)].
Infusion-Related Reactions
Advise patients to contact their healthcare provider if they experience signs and symptoms of infusion reactions, including fever, chills, rash, or breathing problems, within 24 hours of infusion [see Warnings and Precautions (5.2)].
Myelosuppression
Advise patients to report signs or symptoms of bleeding or infection immediately. Advise patients of the need for periodic monitoring of blood counts [see Warnings and Precautions (5.3)].
Infections
Advise patients to contact their healthcare provider if a fever of 38°C (100.4°F) or greater or other evidence of potential infection such as chills, cough, or pain on urination develops. Advise patients of the need for periodic monitoring of blood counts [see Warnings and Precautions (5.4)].
Progressive Multifocal Leukoencephalopathy
Advise patients to seek immediate medical attention for new or changes in neurological symptoms such as confusion, dizziness, or loss of balance; difficulty talking or walking; or changes in vision [see Warnings and Precautions (5.5)].
Tumor Lysis Syndrome
Advise patients to seek immediate medical attention for symptoms of tumor lysis syndrome such as nausea, vomiting, diarrhea, and lethargy [see Warnings and Precautions (5.6)].
Hepatotoxicity
Advise patients to report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice [see Warnings and Precautions (5.7)].
Infusion Site Extravasation Injury
Advise patients to contact their healthcare provider if they experience any signs or symptoms of infusion site extravasation such as burning sensation, tingling, pain, discomfort, swelling or redness at or around the infusion site during or after the treatment with POLIVY [see Warnings and Precautions (5.8)].
Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with POLIVY [see Warnings and Precautions (5.9) and Use in Specific Populations (8.1)].
Females and Males of Reproductive Potential
Advise females of reproductive potential, and males with female partners of reproductive potential, to use effective contraception during treatment with POLIVY and for 3 months and 5 months after the last dose, respectively [see Use in Specific Populations (8.3)].
Lactation
Advise women not to breastfeed while receiving POLIVY and for 2 months after the last dose [see Use in Specific Populations (8.2)].
Infertility
Advise females and males of reproductive toxicity that POLIVY may impair fertility [See Use in Specific Populations (8.3)].
POLIVY® [polatuzumab vedotin-piiq]
Manufactured by:
Genentech, Inc.
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080-4990
POLIVY is a registered trademark of Genentech, Inc.
© 2026 Genentech, Inc.
U.S. License No. 1048
Representative sample of labeling (see the HOW SUPPLIED section for complete listing):